Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the α-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs

Journal of Medicinal Chemistry

Volumn 49, Issue 6, 2006, Pages 2117-2126

  Nishimori, Isao ^a   Minakuchi, Tomoko ^a   Morimoto, Kaori ^a   Sano, Shuichi ^a   Onishi, Saburo ^a   Takeuchi, Hiroaki ^a   Vullo, Daniela ^b   Scozzafava, Andrea ^b   Supuran, Claudiu T ^b  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 6 CHLORO 1,3 BENZENEDISULFONAMIDE; ACETAZOLAMIDE; ANTIULCER AGENT; BENZENESULFONAMIDE DERIVATIVE; BRINZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; DICLOFENAMIDE; DORZOLAMIDE; ETHOXZOLAMIDE; INDISULAM; METHAZOLAMIDE; ORTHANILAMIDE; SULFAMIC ACID DERIVATIVE; SULFANILAMIDE; SULFONAMIDE; SULPIRIDE; TOPIRAMATE; UNCLASSIFIED DRUG; ZONISAMIDE;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; GASTRITIS; GENE SEQUENCE; HELICOBACTER PYLORI; LIPOPHILICITY; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; STOMACH CANCER; STOMACH ULCER; SURVIVAL;

AMINO ACID SEQUENCE; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CLONING, MOLECULAR; DNA, BACTERIAL; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER PYLORI; HUMANS; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS; STOMACH ULCER; SULFONAMIDES; SULFONIC ACIDS;

EID: 33645402549     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0512600     Document Type: Article

References (62)

1. Supuran, C. T.; Scozzafava, A.; Conway, J. Carbonic Anhydrase-Its Inhibitors and Activators; CRC Press: Boca Raton, FL, 2004; pp 1-363.
2. Sly, W. S.; Hu, P. Y. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu. Rev. Biochem. 1995, 64, 375-401.
3. Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran, C. T. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 2004, 19, 199-229.
4. Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev. 2003, 23, 146-89.
5. Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opin. Ther. Pat. 2004, 14, 667-702.
6. Lehtonen, J.; Shen, B.; Vihinen, M.; Casini, A.; Scozzafava, A.; Supuran, C. T.; Parkkila, A. K.; Saarnio, J.; Kivela, A. J.; Waheed, A.; Sly, W. S.; Parkkila, S. Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J. Biol. Chem. 2004, 279, 2719-27.
7. Fujikawa-Adachi, K.; Nishimori, I.; Taguchi, T.; Onishi, S. Human mitochondrial carbonic anhydrase VB. cDNA cloning, mRNA expression, subcellular localization, and mapping to chromosome X. J. Biol. Chem. 1999, 274, 21228-33.
8. Fujikawa-Adachi, K.; Nishimori, I.; Taguchi, T.; Onishi, S. Human carbonic anhydrase XIV (CA14): cDNA cloning, mRNA expression, and mapping to chromosome 1. Genomics 1999, 61, 74-81.
9. (a) Nishimori, I.; Vullo, D.; Innocenti, A.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. J. Med. Chem. 2005, 48, 7860-7866.
10. (b) Vullo, D.; Franchi, M.; Gallori, E.; Antel, J.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J. Med. Chem. 2004, 47, 1272-9.
11. (c) Supuran, C. T. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin. Ther. Pat. 2003, 13, 1545-1550.
12. (a) Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C. T.; Scozzafava, A.; Klebe, G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2 selective Celecoxib: New pharmacological opportunities due to related binding site recognition. J. Med. Chem. 2004, 47, 550-557.
13. (b) Pastorekova, S.; Casini, A.; Scozzafava, A.; Vullo, D.; Pastorek, J.; Supuran, C. T. Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 869-873.
14. (a) Vullo, D.; Voipio, J.; Innocenti, A.; Rivera, C.; Ranki, H.; Scozzafava, A.; Kaila, K.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2005, 15, 971-6.
15. (b) De Simone, G.; Di Fiore, A.; Menchise, V.; Pedone, C.; Antel, J.; Casini, A.; Scozzafava, A.; Wurl, M.; Supuran, C. T. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Biorg. Med. Chem. Lett. 2005, 15, 2315-2320.
16. Vullo, D.; Innocenti, A.; Nishimori, I.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs? Bioorg. Med. Chem. Lett. 2005, 15, 963-9.
17. (a) Svastova, E.; Hulikova, A.; Rafajova, M.; Zat'ovicova, M.; Gibadulinova, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C. T.; Pastorek, J.; Pastorekova, S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577, 439-45.
18. (b) Cecchi, A.; Hulikova, A.; Pastorek, J.; Pastorekova, S.; Scozzafava, A.; Winum, J.-Y.; Montera, J.-L.; Supuran, C. T. Carbonic anhydrase inhibitors. Sulfonamides inhibit isozyme IX mediated acidification of hypoxic tumors. Fluorescent sulfonamides design as probes of membrane-bound carbonic anhydrase isozymes involvement in tumorigenesis. J. Med. Chem. 2005, 48, 4834-4841.
19. (c) Menchise, V.; De Simone, G.; Alterio, V.; Di Fiore, A.; Pedone, C.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: Stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J. Med. Chem. 2005, 48, 5721-5727.
20. Krungkrai, J.; Scozzafava, A.; Reungprapavut, S.; Krungkrai, S. R.; Rattanajak, R.; Kamchonwongpaisan, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic sulfonamides: towards antimalarials with a novel mechanism of action? Bioorg. Med. Chem. 2005, 13, 483-489.
21. (a) Suarez Covarrubias, A.; Larsson, A. M.; Hogbom, M.; Lindberg, J.; Bergfors, T.; Bjorkelid, C.; Mowbray, S. L.; Unge, T.; Jones, T. A. Structure and function of carbonic anhydrases from Mycobacterium tuberculosis. J. Biol. Chem. 2005, 280, 18782-9.
22. (b) Suarez Covarrubias, A.; Bergfors, T.; Jones, T. A.; Hogbom, M. Structural mechanics of the pH dependent activity of beta-carbonic anhydrase from Mycobacterium tuberculosis. J. Biol. Chem. 2006, in press.
23. 2 Sensing with cAMP Signaling and Virulence. Curr. Biol. 2005, 15, 2021-2026.
24. (b) Mogensen, E. G.; Janbon, G.; Chaloupka, J.; Steegborn, C.; Fu, M. S.; Moyrand, F.; Klengel, T.; Pearson, D. S.; Geeves, M. A.; Buck, J.; Levin, L. R.; Muhlschlegel F. A. Cryptococcus neoformans Senses CQi through the Carbonic Anhydrase Can2 and the Adenylyl Cyclase Cacl. Eukaryot. Cell 2006, 5, 103-111.
25. Bahn, Y. S.; Cox, G. M.; Perfect, J. R.; Heitman, J. Carbonic Anhydrase and CCh Sensing during Cryptococcus neoformans Growth, Differentiation, and Virulence. Curr. Biol. 2005, 15, 2013-2020.
26. (a) Marshall, B. J.; Warren, J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984, 16, 1311-1315.
27. (b) Marshall, B. J. Helicobacter pylori. Am. J. Gastroenterol. 1994, 89, S116-S128.
28. (a) Personnet, J.; Friedman, G. D.; Vandersteen, D. P.; Chang, Y.; Vogelman, J. H.; Orentreich, N.; Sibley, R. K. H. pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 1991, 325, 1131.
29. (b) Moss, S. F.; Blaser, M. J. Mechanisms of disease: Inflammation and the origins of cancer. Nat. Clin. Pract. Oncol. 2005, 2, 90-97.
30. (c) Kountouras, J.; Zavos, C.; Chatzopoulos, D. New concepts of molecular biology on gastric carcinogenesis. Hepatogastroenterology 2005, 52, 1305-12.
31. (d) Marshall, B. J.; Windsor, H. M. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med. Clin. North Am. 2005, 89, 313-44.
32. (a) O'Mahony, R.; Vaira, D.; Holton, J.; Basset, C. Helicobacter pylori: current status and future prospects. Sci. Prog. 2004, 87, 269-96.
33. (b) Megraud, F.; Marshall, B. J. How to treat Helicobacter pylori. First-line, second-line, and future therapies. Gastroenterol. Clin. North Am. 2000, 29, 759-73.
34. Gisbert, J. P.; Pajares, J. M. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter 2005, 10, 363-72.
35. Nakayama, Y.; Graham, D. Y. Helicobacter pylori infection: diagnosis and treatment. Expert Rev. Anti-Infect. Ther. 2004, 2, 599-610.
36. (a) Megraud, F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 2004, 64, 1893-1904.
37. (b) Loughlin, M. F. Novel therapeutic targets in Helicobacter pylori. Expert Opin. Ther. Targets 2003, 7, 725-735.
38. Sachs, G.; Weeks, D. L.; Wen, Y.; Marcus, E. A.; Scott, D. R.; Melchers, K. Acid acclimation by Helicobacter pylori. Physiology (Bethesda) 2005, 20, 429-438.
39. Marcus, E. A.; Moshfegh, A. P.; Sachs, G.; Scott, D. R. The periplasmic alpha-carbonic anhydrase activity of Helicobacter pylori is essential for acid acclimation. J. Bacteriol. 2005, 187, 729-738.
40. Stahler, F. N.; Ganter, L.; Lederer, K.; Kist, M.; Bereswill, S. Mutational analysis of the Helicobacter pylori carbonic anhydrases. FEMS Immunol. Med. Microbiol. 2005, 44, 183-189.
41. (a) Chirica, L. C.; Elleby, B.; Lindskog, S. Cloning, expression and some properties of alpha-carbonic anhydrase from Helicobacter pylori. Biochim. Biophys. Acta 2001, 1544, 55-63.
42. (b) Chirica, L. C.; Petersson, C.; Hurtig, M.; Jonsson, B. H.; Boren, T.; Lindskog, S. Expression and localization of alpha- and beta-carbonic anhydrase in Helicobacter pylori. Biochim. Biophys. Acta 2002, 1601, 192-199.
43. Supuran, C. T.; Scozzafava, A.; Casini, A. Development of sulfonamide carbonic anhydrase inhibitors. In Carbonic anhydrase-Its inhibitors and activators; Supuran, C. T., Scozzafava, A., Conway, J., Eds.; CRC Press: Boca Raton, FL, 2004; pp 67-147.
44. ENTREZ Genome project: Helicobacter pylori J99 project at ASTRA; http://www.ncbi.nlm.nih.gov/entrez/query.
45. The Institute for Genomic Research (TIGR), the Comprehensive Microbial Resource (CMR) Home Page; http://cmr.tigr.org/tigrscripts/CMR/CmrHomePage.cgi.
46. Tomb, J. F.; White, O.; Kerlavage, A. R.; Clayton, R. A.; Sutton, G. G.; Fleischmann, R. D.; Ketchum, K. A.; Klenk, H. P.; Gill, S.; Dougherty, B. A.; Nelson, K.; Quackenbush, J.; Zhou, L.; Kirkness, E. F.; Peterson, S.; Loftus, B.; Richardson, D.; Dodson, R.; Khalak, H. G.; Glodek, A.; McKenney, K.; Fitzegerald, L. M.; Lee, N.; Adams, M. D.; Hickey, E. K.; Berg, D. E.; Gocayne, J. D.; Utterback, T. R.; Peterson, J. D.; Kelley, J. M.; Cotton, M. D.; Weidman, J. M.; Fujii, C.; Bowman, C.; Watthey, L.; Wallin, E.; Hayes, W. S.; Borodovsky, M.; Karp, P. D.; Smith, H. O.; Fraser, C. M.; Venter, J. C. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997, 388, 539-547.
47. Casini, A.; Antel, J.; Abbate, F.; Scozzafava, A.; David, S.; Waldeck, H.; Schafer, S.; Supuran, C. T. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg. Med. Chem. Lett. 2003, 13 (5), 841-5.
48. Abbate, F.; Coetzee, A.; Casini, A.; Ciattini, S.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. Bioorg. Med. Chem. Lett. 2004, 14 (2), 337-41.
49. Abbate, F.; Casini, A.; Owa, T.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 217-23.
50. Hies, M. A.; Vullo, D.; Pastorek, J.; Scozzafava, A.; Hies, M.; Caproiu, M. T.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. J. Med. Chem. 2003, 46, 2187-96.
51. Scozzafava, A.; Briganti, F.; Mincione, G.; Menabuoni, L.; Mincione, F.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. J. Med. Chem. 1999, 42, 3690-700.
52. Scozzafava, A.; Menabuoni, L.; Mincione, F.; Briganti, F.; Mincione, G.; Supuran, C. T. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J. Med. Chem. 1999, 42, 2641-50.
53. Supuran, C. T.; Clare, B. W. Quantum theoretic QSAR of benzene derivatives: some enzyme inhibitors. J. Enzyme Inhib. Med. Chem. 2004, 19, 237-48.
54. Winum, J. Y.; Dogne, J. M.; Casini, A.; de Levai, X.; Montera, J. L.; Scozzafava, A.; Vullo, D.; Innocenti, A.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties. J. Med. Chem. 2005, 48, 2121-5.
55. Khalifah, R. G.; Strader, D. J.; Bryant, S. H.; Gibson, S. M. Carbon-13 nuclear magnetic resonance probe of active-site ionizations in human carbonic anhydrase B. Biochemistry 1977, 16, 2241-7.
56. Khalifah, R. G. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J. Biol. Chem. 1971, 246, 2561-73.
57. (a) Puscas, I. Carbonic anhydrase and inhibition of gastric secretion by acetazolamide. Med. Interna 1973, 25, 1243-1252.
58. (b) Puscas, I.; Paun, R.; Ursea, N.; Dragomir, N.; Roscin, M. Les inhibiteurs de l'anhydrase carbonique dans le traitement de l'ulcere gastrique et duodenal. Arch. Fr. Mal Appar. Dig. 1976, 65, 577-583.
59. (c) Puscas, I. Treatment of gastroduodenal ulcers with carbonic anhydrase inhibitors. Ann. N.Y. Acad. Sci. 1984, 429, 587-591.
60. (d) Puscas, I. Treatment of gastroduodenal ulcers with inhibitors of gastric mucosa carbonic anhydrase. In Carbonic Anhydrase and Modulation of Physiologic and Pathologic Processes in the Organism; Puscas, I., Ed.; Helicon Press: Timisoara, Romania, 1994; pp 438-450.
61. Maren, T. H. Carbonic anhydrase: Chemistry, physiology and inhibition. Physiol. Rev. 1967, 47, 595-781.
62. Sano, S.; Nishimori, I.; Kosaki, T.; Fujikawa-Adachi, K.; Onishi, S. The fine form of Helicobacter pylori on the metaplastic duodenal mucosa is associated with recurrent duodenal ulcers. Digestion 2001, 64, 161-8.